GABAAR-PPT1 palmitoylation homeostasis controls synaptic transmission and circuitry oscillation
Jia Tong1,2, Jingjing Gao2,3, Yawei Qi2
1The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, He'nan, China.
Insights
Palmitoyl protein thioesterase 1 (PPT1) depalmitoylates GABAAR, a key inhibitory neurotransmission protein. PPT1 mutations impair learning and memory, revealing a new molecular pathway in CLN1 disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Infantile neuronal ceroid lipofuscinosis (CLN1 disease) is a fatal neurodegenerative disorder.
- Mutations in the CLN1 gene, encoding palmitoyl protein thioesterase 1 (PPT1), cause CLN1 disease.
- Identifying PPT1 substrates is crucial for understanding CLN1 disease pathogenesis.
Purpose of the Study:
- To identify depalmitoylation substrates of PPT1.
- To investigate the role of PPT1 in regulating GABAAR palmitoylation.
- To elucidate the molecular mechanisms underlying CLN1 disease.
Main Methods:
- Biochemical assays to identify PPT1 substrates.
- Analysis of GABAAR α1 subunit palmitoylation.
- Electrophysiological recordings in mouse models.
- Behavioral tests for learning and memory.
Main Results:
- GABAAR was identified as a substrate of PPT1.
- PPT1 depalmitoylates the GABAAR α1 subunit at Cys-260 and binds to Cys-165 and -179.
- PPT1 deficiency or mutations impaired learning and memory in mice.
- Disrupted synaptic transmission and oscillations were observed in the CA1 region.
Conclusions:
- PPT1 plays a critical role in maintaining GABAAR palmitoylation homeostasis.
- PPT1 mutations disrupt inhibitory neurotransmission and cognitive function.
- A novel molecular pathway involving PPT1 and GABAAR in CLN1 disease has been revealed.
Abstract:
The infantile neuronal ceroid lipofuscinosis, also called CLN1 disease, is a fatal neurodegenerative disease caused by mutations in the CLN1 gene encoding palmitoyl protein thioesterase 1 (PPT1). Identifying the depalmitoylation substrates of PPT1 is crucial for understanding CLN1 disease. In this study, we found that GABAAR, the critical synaptic protein essential for inhibitory neurotransmission, is a substrate of PPT1. PPT1 depalmitoylates GABAAR α1 subunit at Cystein-260, while binding to Cystein-165 and -179. Mutations of PPT1 or its GABAAR α1 subunit binding site enhanced inhibitory synaptic transmission and strengthened oscillations powers but disrupted phase coupling in CA1 region and impaired learning and memory in 1- to 2-months-old PPT1-deficient and Gabra1em1 mice. Our study highlights the critical role of PPT1 in maintaining GABAAR palmitoylation homeostasis and reveals a previously unknown molecular pathway in CLN1 diseases induced by PPT1 mutations.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
G-Protein Gated Ion Channels
Sensory...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Activation and Inactivation of G Proteins
GPCR Desensitization
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...


